Skip to main
STE

STERIS (STE) Stock Forecast & Price Target

STERIS (STE) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Steris is expected to see steady growth in all three segments, with potential for margin expansion as the company invests in new facilities and efficiency-enhancing technologies. The company's initial FY27 organic growth guidance of 6-7% and EPS guidance ahead of Street expectations show a strong outlook for the company. Furthermore, Steris is continuing to invest in capital allocation initiatives and has the potential for sustainable margin expansion of ~50 bps annually.

Bears say

Steris is highly reliant on its healthcare services segment for revenue, which brings in 70% of its total revenue. However, this segment is facing headwinds as demonstrated by the slower growth in capital equipment shipments and a backlog that has remained relatively stagnant. Despite a recent investment in a new facility, there are concerns about the company's ability to achieve strong efficiency gains and hit targeted ROIC levels within a reasonable timeframe. Additionally, the company's recent bolt-on acquisitions in its healthcare products segment may not contribute significant revenue, and we question the effectiveness of their new $1B share buyback program given their high leverage ratio and potential future investment needs.

STERIS (STE) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STERIS (STE) Forecast

Analysts have given STERIS (STE) a Buy based on their latest research and market trends.

According to 3 analysts, STERIS (STE) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $271.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $271.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STERIS (STE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.